Journal
HAEMATOLOGICA
Volume 107, Issue 3, Pages 604-614Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2020.265777
Keywords
-
Categories
Funding
- DFG [SFB1074]
- ERA-NET FIRE-CLL
- ERA-NET FIRE-CLL
- BMBF PRECISE
- AbbVie
- AstraZeneca
- Celgene
- Gilead
- GSK
- Hoffmann La-Roche
- Janssen
- Novartis
Ask authors/readers for more resources
Clonal evolution plays a significant role in the progression of CLL. Long-term longitudinal mutation profiling study revealed distinct evolutionary patterns, with minor clonal shifts in stable disease and relapse after long-lasting treatment response, but major clonal shifts in refractory disease. These shifts are not strongly linked to known CLL driver genes, suggesting that they are mostly driven by treatment-induced selection of sub-clones, highlighting the need for novel non-genotoxic treatment regimens.
Clonal evolution is involved in the progression of chronic lymphocytic leukemia (CLL). In order to link evolutionary patterns to different disease courses, we performed a long-term longitudinal mutation profiling study of CLL patients. Tracking somatic mutations and their changes in allele frequency over time and assessing the underlying cancer cell fraction revealed highly distinct evolutionary patterns. Surprisingly, in long-term stable disease and in relapse after long-lasting clinical response to treatment, clonal shifts are minor. In contrast, in refractory disease major clonal shifts occur although there is little impact on leukemia cell counts. As this striking pattern in refractory cases is not linked to a strong contribution of known CLL driver genes, the evolution is mostly driven by treatment-induced selection of sub-clones, underlining the need for novel, non-genotoxic treatment regimens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available